focus -WSS

focus

author：knowledge 2025-10-02 03:32:05 - browse：11665

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Wegovy cuts risk of cardiovascular events by 20%, study finds

hotspot

WSS

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Nick Jonas talks about managing diabetes along with his career

Better Therapeutics data on benefit with GLP

More regulation could be coming for drug ads

Female surgeons have lower rates of long

The painfully weak evidence on taking collagen to treat arthritis

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

explore

In age of alternative facts, a scholarly course on calling out crap

What the Wegovy shortage looks like for doctors — and for patients

ChatGPT in medicine: STAT answers readers' burning questions

Wegovy cuts risk of cardiovascular events by 20%, study finds

What does generative AI mean for health care? We asked experts

In venture capital firm's success, lessons for turning crisis into profit

Activists slam private health insurers over coverage restrictions

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Trump demands the U.S. pay no more for drugs than other countries … again

More regulation could be coming for drug ads

hotspot

Astronauts get first look at the spacecraft that will fly them around the moon

Judge rejects Trump's counterclaim against E. Jean Carroll

Zapping the brain for stroke rehab: Pivotal clinical trial begins

What's changing in Medicare's open enrollment this year?

Researchers CRISPR chickens in bid to protect them from bird flu

Cancer cells are shown to suck energy source from immune cells

hotspot

hotspot

hotspot

hotspot